Cargando…

Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer

BACKGROUND: As a rare subtype of lung adenocarcinoma, the diagnosis of pulmonary enteric adenocarcinoma (PEAC) remains challenging due to overlapping morphologic spectrum with lung metastatic colorectal cancer (lmCRC). However, the molecular features of PEAC as a separate lung cancer entity are poor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuo, Ying, Zhong, Jia, Bai, Hua, Xu, Bin, Wang, Zhijie, Li, Weihua, Chen, Yedan, Jin, Shi, Wang, Shuhang, Wang, Xin, Wan, Rui, Xu, Jiachen, Fei, Kailun, Han, Jiefei, Yang, Zhenlin, Bao, Hua, Shao, Yang, Ying, Jianming, Song, Qibin, Duan, Jianchun, Wang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334343/ https://www.ncbi.nlm.nih.gov/pubmed/35901658 http://dx.doi.org/10.1016/j.ebiom.2022.104165

Ejemplares similares

Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer: A Phase 1 Trial
por: Wang, Zhijie, et al.
Publicado: (2020)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
por: Bai, Hua, et al.
Publicado: (2020)

A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinoma
por: Xu, Jiachen, et al.
Publicado: (2023)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
por: Tian, Yanhua, et al.
Publicado: (2020)

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy
por: Zhao, Jie, et al.
Publicado: (2023)

Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment
por: Wang, Chao, et al.
Publicado: (2023)

Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers
por: Han, Jiefei, et al.
Publicado: (2021)

Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
por: Zhao, Zhe, et al.
Publicado: (2020)

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
por: Zhang, Pei, et al.
Publicado: (2022)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer
por: Tian, Yanhua, et al.
Publicado: (2022)

Hypoxia‐inducible factor‐1α and nuclear factor‐κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non‐small‐cell lung cancer cells
por: Guo, Rong, et al.
Publicado: (2019)

Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
por: Cai, Liangliang, et al.
Publicado: (2019)

Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer
por: Du, Jun, et al.
Publicado: (2021)

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
por: Yu, Ruofei, et al.
Publicado: (2021)

Pulmonary enteric adenocarcinoma
por: Gong, Jiali, et al.
Publicado: (2021)

Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma
por: Li, Zhenxiang, et al.
Publicado: (2015)

Entering the post-epigenomic age: back to epigenetics
por: Bultmann, Sebastian, et al.
Publicado: (2018)

Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2020)

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
por: Du, Xinyang, et al.
Publicado: (2022)

Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
por: Sun, Boyang, et al.
Publicado: (2023)

Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity
por: Liu, Lihui, et al.
Publicado: (2023)

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
por: Zhu, Jian, et al.
Publicado: (2012)

Comprehensive Genomic and Epigenomic Analyses on Transcriptomic Regulation in Stomach Adenocarcinoma
por: Chen, Junxing, et al.
Publicado: (2022)

Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas
por: Sun, Sijin, et al.
Publicado: (2021)

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
por: Cai, Liangliang, et al.
Publicado: (2020)

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
por: Wang, Zhijie, et al.
Publicado: (2014)

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer
por: Zhang, Pei, et al.
Publicado: (2020)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
por: Wang, Shuhang, et al.
Publicado: (2015)

Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2022)

Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma
por: Zhao, Yue, et al.
Publicado: (2021)

Diagnosis and treatment of primary pulmonary enteric adenocarcinoma: Report of Six cases
por: Tu, Ling-Fang, et al.
Publicado: (2021)

Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq
por: Li, Qingqing, et al.
Publicado: (2022)

Comprehensive data analysis of genomics, epigenomics, and transcriptomics to identify specific biomolecular markers for prostate adenocarcinoma
por: Ye, Chunwei, et al.
Publicado: (2021)

EWASdb: epigenome-wide association study database
por: liu, Di, et al.
Publicado: (2019)

Plastin-3 is a diagnostic and prognostic marker for pancreatic adenocarcinoma and distinguishes from diffuse large B-cell lymphoma
por: Xiong, Fei, et al.
Publicado: (2021)

Development and psychometric testing of a questionnaire to assess Nurse’s perception of risks during enteral nutrition
por: Feng, Ping, et al.
Publicado: (2021)

Editorial: Application of epigenomics data to improve human and livestock health
por: Wang, Xiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_02rrc73bk0jmp0ti3fgs674bpm